Additionally, a prime-boost regimen of SFV-OVA and VV-OVA resulted in enhanced OVA-specific CD8+ T cell immune responses and enhanced anti-tumor activity in immunized C57BL/6 mice with implanted murine ovarian surface epithelial carcinoma (MOSEC) [135]. Here, CD8A is linked to neoplasm.